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Background: Clomiphene citrate (CC) is first line treatment in women with World Health Organization (WHO) type
II anovulation and polycystic ovary syndrome (PCOS). Whereas 60% to 85% of these women will ovulate on CC,
only about one half will have conceived after six cycles. If women do not conceive, treatment can be continued
with gonadotropins or intra-uterine insemination (IUI). At present, it is unclear for how many cycles ovulation
induction with CC should be repeated, and when to switch to ovulation induction with gonadotropins and/or IUI.
Methods/Design: We started a multicenter randomised controlled trial in the Netherlands comparing six cycles of
CC plus intercourse or six cycles of gonadotrophins plus intercourse or six cycles of CC plus IUI or six cycles of
gonadotrophins plus IUI.
Women with WHO type II anovulation who ovulate but did not conceive after six ovulatory cycles of CC with a
maximum of 150 mg daily for five days will be included.
Our primary outcome is birth of a healthy child resulting from a pregnancy that was established in the first eight months
after randomisation. Secondary outcomes are clinical pregnancy, miscarriage, multiple pregnancy and treatment costs.
The analysis will be performed according to the intention to treat principle. Two comparisons will be made, one in which
CC is compared to gonadotrophins and one in which the addition of IUI is compared to ovulation induction only.
Assuming a live birth rate of 40% after CC, 55% after addition of IUI and 55% after ovulation induction with
gonadotrophins, with an alpha of 5% and a power of 80%, we need to recruit 200 women per arm (800 women in total).
An independent Data and Safety Monitoring Committee has criticized the data of the first 150 women and concluded
that a sample size re-estimation should be performed after including 320 patients (i.e. 80 per arm).
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Discussion: The trial will provide evidence on the most effective, safest and most cost effective treatment in women
with WHO type II anovulation who do not conceive after six ovulatory cycles with CC with a maximum of 150 mg
daily for five days. This evidence could imply the need for changing our guidelines, which may cause a shift in large
practice variation to evidence based primary treatment for these women.
Trial registration number: Netherlands Trial register NTR1449Background
There is a lack of evidence on how to best treat women
with World Health Organization (WHO) type II ano-
vulation or polycystic ovary syndrome (PCOS) and clo-
miphene citrate (CC) failure. Women with WHO type II
anovulation have absent or irregular ovulation due to
hypothalamic-pituitary dysfunction associated with nor-
mal levels of endogenous estradiol. The majority of these
women can be diagnosed with PCOS. The diagnosis of
PCOS is based on at least two of the following three cri-
teria: oligo-ovulation or anovulation, clinical or bio-
chemical evidence of hyperandrogenism, and polycystic
ovaries on ultrasound assessment [1].
CC has been used as a first-line ovulation induction
agent for over 40 years [2,3]. Systematic reviews and meta-
analyses have shown that CC is indeed the best primary
treatment option in therapy-naive women with WHO type
II anovulation and PCOS [4-8]. Although 60% to 85% of
women starting ovulation induction with CC will ovulate,
only about one half will have conceived after six cycles
[9,10] the so called women with CC-failure.
When anovulatory women ovulate after CC, but do
not conceive after six cycles, the clinical problem occurs,
that cannot be answered by guidelines. Most trials, ran-
domised or not, have been directed at therapy naïve
women, or at women with PCOS that remained anovula-
tory after CC, also called CC-resistant women [11-18].
For CC-failure, on one hand, women may continue to
use CC for another six cycles. On the other hand, they may
switch to ovulation induction with gonadotrophins. Both
types of ovulation induction may involve intercourse or
may be combined with intra-uterine insemination (IUI).
A reason why women should continue CC with regular
intercourse is that women do still get pregnant on CC
after six treatment cycles, although pregnancy rates per
cycle probably drop despite regular ovulation [2,19].
There is consensus that it is best to limit exposure to CC
to 12 treatment cycles, as additional cycles may place the
woman at increased risk of borderline ovarian tumours
[20]. Although it is thus clear that for safety reasons the
upper limit of treatment cycles is 12, it is unclear for how
many cycles ovulation induction with CC should be re-
peated from the perspective of effectiveness.
Several studies and one report of an international con-
sensus meeting advise continuation of treatment withgonadotrophins and/or IUI if pregnancy does not
occur within six ovulatory cycles [21-24]. This advice
is based upon the presumption that lack of conception
despite evidence of ovulation may be due to anti-
estrogenic effects of CC on the endometrium.
Pregnancy rates with gonadotrophins can be expec-
ted to be higher than with CC in women that do not
conceive after six ovulatory cycles on CC. The down-
side is that ovulation induction with gonadotrophins
has major disadvantages. It implies daily injections of
gonadotrophins combined with concurrent blood and
ultrasound monitoring of follicular growth and deve-
lopment. Multifollicular development is not uncom-
mon, despite careful dose adjustment and monitoring,
due to the inherent nature of PCOS. Also, injectable
gonadotrophins are expensive and the frequent mo-
nitoring of follicular growth implies substantial additional
cost. Extra costs are generated because treatment cycles
often have to be cancelled to minimize the risks of mul-
tiple pregnancy and, more rarely, of ovarian hyperstimula-
tion syndrome [25,26].
In IUI motile spermatozoa are concentrated and
placed directly into the uterine cavity, in closer prox-
imity to the released oocyt than is the case after vagi-
nal intercourse. There have been no randomised
controlled trials that studied the effect of IUI in
women undergoing ovulation-induction with CC or
gonadotrophins for oligo- or anovulation. Still, IUI is
often added to ovulation induction with CC or go-
nadotrophins. The NICE guidelines actually recom-
mend IUI and prolonged ovulation induction with
CC in women who ovulate on CC but do not conceive
[27]. IUI is expected to result in higher pregnancy
rates than intercourse but requires extra laboratory
work and more hospital visits and is therefore much
more expensive.
In summary, in women with WHO type II anovulation
or PCOS who ovulate on CC but fail to conceive after six
ovulatory cycles, prolonged CC or a switch to gonadotro-
phins, as well as the addition of IUI are treatment options
that are often applied in clinical practice. However, data
on cost and effectiveness of these options are lacking. We
therefore propose to determine which treatment is most
cost-effective, thus facilitating a cost-effective and standar-
dised clinical practice in The Netherlands.
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Our primary objective is to evaluate four treatment regi-
mens in women with WHO type II anovulation that failed
to conceive after six ovulatory cycles with CC in terms of
singleton live birth. Secondary objectives are to assess the
safety and cost-effectiveness for these treatment regimens
and to optimise guideline recommendations.
Methods
Participating centres
This study is a multicentre randomised controlled trial in
The Netherlands and inclusion started in December 2008.
Inclusion criteria
We will include women with WHO type II anovulation,
who have been ovulatory for six cycles on CC treatment,
with a maximum of 150 mg daily for five days, but who did
not conceive. Ovulation will be assessed by a basal tem-
perature curve, midluteal progesterone (> 16 nmol/l), detec-
tion of LH surge or sonography, depending on the local
protocol. All women will have at least one patent Fallopian
tube, proven by negative Chlamydia antibody titre (CAT),
hysterosalpingography (HSG), transvaginal hydrolaparoscopy
(THL) or diagnostic laparoscopy combined with tubal test-
ing (DLS and TT), also depending on the local protocol.
Exclusion criteria
We will not include women below 18 years, women with
abnormal prolactin or thyroid-stimulating hormone va-
lues, women with intolerable symptoms when treated
with CC like hot flashes affecting daily function, head-
aches, vision changes, or depression and women who re-
main anovulatory on CC 150 mg daily for five days, the
so called CC-resistant women.
Ethical considerations
Approval for this study was obtained from the Medical
Ethical Committee of the Medical Spectrum Twente En-
schede and from the Central Committee on Research in-
volving Human Subjects (CCMO), The Netherlands. In
women fulfilling the inclusion criteria, written informed
consent is obtained before randomisation is carried out.
Randomisation
Randomisation is performed by accessing a password
protected central internet-based randomisation program
and is stratified for hospital. The randomisation list is
prepared by an independent statistician. A 2x2 factorial
design will be used. This will create four groups:
1) CC plus intercourse
2) CC plus IUI
3) gonadotrophins plus intercourse
4) gonadotrophins plus IUIStudy management
All women participating in the study will undergo a
basic fertility work-up including a semen-analysis and
endocrinological investigation to rule out hyperprolacti-
nemia and uncorrected thyroid dysfunction. Ovulation is
induced with CC. From the third or fifth day until the
seventh or ninth day after spontaneous or progesterone
induced menstruation women will take CC with a mini-
mum of 50 mg to a maximum of 150 mg a day. During
the first six treatment cycles women will undergo CAT,
HSG, THL and/or DLS and TT to exclude double sided
tubal occlusion.
Women are eligible for the study after six ovulatory
cycles proven by a cycle length of less than 35 days, a bi-
phasic basal temperature curve, midluteal progesterone
(> 16 nmol/l), detection of LH surge or sonography, de-
pending on the local protocol.
Women eligible for the study will be referred to a re-
search nurse for counselling and randomisation.
Interventions
Women are allocated to a treatment strategy consisting
of six cycles of CC plus intercourse or six cycles of go-
nadotrophins plus intercourse or six cycles of CC plus
IUI or six cycles of gonadotrophins plus IUI. Women
are treated until a pregnancy occurs within a treatment
time horizon of eight months resulting in the birth of a
healthy child (Figure 1).
Ovulation induction, semen preparation and insem-
ination regimens will be done according to hospital
specific protocols. Ovulation induction with CC will
be started on the third to fifth day of a spontaneous
menstrual or progesterone induced bleed, in the same
dosage as used in the last ovulatory cycle, with a mini-
mum of 50 mg to a maximum of 150 mg daily, for five
days. If ovulation does not occur, the dosage will be in-
creased with steps of 50 mg with a maximum of 150
mg daily in the next cycles. As couples are assumed to
have regular intercourse, no specific timing advice
will be given. Only if couples have a history of sexual
problems they are advised to have regular intercourse,
at least three times a week. Ovulation will be docu-
mented according to local protocol with either a bi-
phasic temperature curve, or a follicle with a diameter ≥16
mm ;on transvaginal ultrasonography. In case of ovulation
women will continue taking the same dose of CC until an
end point is reached.
Ovulation induction with gonadotrophins will be
started at the second to fifth day of a spontaneous
or progesterone induced menstrual bleed according
to the established chronic low dose step up regi-
men. Transvaginal ultrasound will be performed on
day three of the cycle or according to local pro-
tocol. Women will not be stimulated if they have
Figure 1 Flow chart M-OVIN study.
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dose will be 50 or 75 IU daily. The follicular growth is
strictly monitored by transvaginal ultrasound. If more
than three dominant follicles (≥18 mm) are present,
the cycle will be cancelled. When at least one follicle
with a diameter of ≥ 16 mm is present, ovulation is
induced by the administration of 5000 IU or 10000 IU
of human chorionic gonadotrophin (hCG) followed by
timed intercourse.
In case of IUI, semen samples will be processed
within one hour of ejaculation by density gradient cen-
trifugation followed by washing with culture medium.
Women will be inseminated 36 hours after hCG injec-
tion. IUI will be performed once per cycle.Follow up
Pregnant women will undergo an ultrasound at 7 and 11
weeks of gestation to classify the pregnancy as clinical or
ongoing singleton or multiple pregnancy.
Women will be contacted by telephone to enquire on
the pregnancy, delivery and the health of the child.
Detailed information on maternal complication will be
obtained from the obstetrician treating the woman con-
cerned. The focus will be on gestational diabetes and
hypertensive disorders. When necessary, child health cen-
tres and/or paediatricians will then be contacted for spe-
cific information. Certainly not all couples will complete
the 8 months of treatment. Drop-outs will largely repre-
sent normal patient flow. We aim to keep track of all
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in the database.
A structured case record form (CRF) is used to regis-
ter reproductive outcome, fertility treatments as well as
the course and outcome of subsequent pregnancies.
Withdrawal of individual patients
Women can leave the study at any time for any reason if
they wish to do so. Women who drop out of the study
will be asked to provide the reason for dropping out.
This reason will be recorded. Women who drop out of




The main primary outcome measure will be birth of a
healthy child resulting from a pregnancy that was estab-
lished in the first eight months after randomisation. A
live birth is defined as any ongoing pregnancy with a
gestation time beyond 24 weeks. After randomisation
women will receive a maximum of six treatment cycles.
Secondary outcome measures
 Multiple pregnancy, defined as a registered heart
beat of at least two fetuses at 12 weeks of gestation.
 Clinical pregnancy, defined as any registered heart
beat at sonography.
 Miscarriage, defined as loss of an intra uterine
pregnancy (confirmed by ultrasound or histological
examination) before the 20th week of pregnancy.
 Ovulation rates, assessed by a biphasic basal
temperature curve, midluteal progesterone (> 16
nmol/l), detection of LH surge or sonography.
Background and demographic characteristics
To assess whether the treatment groups are balanced,
the study populations will be compared for baseline
measurements including female age, type of infertility
(primary/secondary), duration of infertility, intoxications,
body mass index, as well as sperm analysis according to
WHO standards.
Analysis
The analysis of all outcomes is on an intention to treat
basis. Couples will be treated within a time horizon of eight
months. Two comparisons will be made, one in which
CC is compared to gonadotrophins and one in which the
addition of IUI is compared to ovulation induction only.
Differences in pregnancy outcomes will be expressed in
relative risks with corresponding 95% confidence inter-
vals. Birth rates over time will be compared using life
tables. Discrete variables (e.g. presence of absence of acomplication) will be summarised by frequencies and
proportions. Differences between groups with respect to
discrete variables will be evaluated by using chi-squared
tests. Continuous variables will be assessed for normality
and equality of variance between groups. For continuous
variables, analysis of variance and/or regression will be
used where appropriate.
Economic evaluation
The economic evaluation will be performed alongside the
clinical trial. The economic evaluation will be designed as a
cost-effectiveness analysis of the addition of IUI, use of go-
nadotrophins or the combination of both as compared to
CC alone, with the costs per singleton pregnancy within
eight months after randomisation resulting in live birth as
the primary outcome measure. We will also assess the time
to a successful pregnancy in the cost-effectiveness analysis.
In this analysis, costs and effects will be discounted for 4%
per year.
Determining costs
The economic analysis will be performed from a societal
perspective. A distinction will be made between costs of
medical interventions (direct costs) and costs resulting
from productivity losses (indirect or time costs). Stan-
dardised unit costs will be calculated for all centres
based on actual expenses made during the study. Subse-
quently, unit costs will be applied to resource use as ob-
served in participating centres. Resource utilisation will
be documented using individual patient data in the
CRF’s. Detailed information on complications will be ob-
tained. Resource unit prices will reflect the unit of staff,
materials, equipment, housing, depreciation and over-
head. Productivity loss will be valued using Dutch refer-
ence data (hand book of the Dutch health council).
Costs will be presented in Euros.
For each cost category, costs are measured as the vol-
umes of resources used multiplied with appropriate valua-
tions (unit-costs). Unit costs will be estimated according
to the Dutch guideline on (unit) costing in health care
(Oostenbrink, Bouwmans etal., 2004). Visits to GPs, med-
ical specialists and paramedical care, and travelling will be
valued based on the guideline prices. The friction cost
method will be used to estimate the duration of lost prod-
uctivity, age adjusted average daily wages will be used to
value this duration. An analysis based on reimbursement
fees is added (insurer perspective). Study-specific costs are
excluded from analysis.
Cost-effectiveness analysis
Cost-effectiveness of each strategy will be expressed as
costs per live birth. The incremental cost-effectiveness
ratio (ICER), reflecting the extra costs required to obtain
one additional live birth of each individualized treatment
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the ratio between difference in costs between strategies
and the difference in pregnancy rates. A decision
model will be used to evaluate the optimal strategy
when also taking into account differences in multiple
pregnancies, where the relative importance of different
outcomes can be varied in order to evaluate whether
this affects the results.
Robustness of the results (costs and health outcomes)
for various assumptions and parameter estimates will be
explored in sensitivity analyses and visualized in ICER-
graphs and cost-effectiveness acceptability curves. In the
economic analyses, we will also explore differences in
patient characteristics (e.g. age, parity, ethnicity), as both
costs as well as the treatment effect might differ between
various groups.Power calculation
The analysis will be by intention to treat. Two compari-
sons will be made, one in which CC is compared to go-
nadotrophins and one in which the addition of IUI is
compared to ovulation induction only. Assuming a live
birth rate of 40% after CC, 55% after addition of IUI and
55% after ovulation induction with gonadotrophins, with
an alpha of 5% and a power of 80%, we need to recruit
200 women per arm (800 women in total).
An independent Data and Safety Monitoring Commit-
tee has criticized the data of the first 150 women and
concluded that a sample size re-estimation should be
performed after including 320 patients (i.e. 80 per arm).Discussion
Subfertility occurs in 15,000 new couples in The
Netherlands each year. In one-third of cases (about 5,000
women) this is due to anovulation because of WHO type
II anovulation or PCOS. We estimate that annually 1,500
to 2,000 women will not have conceived after six cycles of
CC, despite regular ovulation.
For women ovulating on CC but failing to conceive, no
consensus exists on the optimal policy. All trials, rando-
mised or not, have been directed at therapy naïve women,
or at women with WHO type II anovulation or PCOS
who remained anovulatory after CC, also called CC-
resistant women. Women with who actually do ovulate
on CC but do not conceive represent a larger group than
CC-resistant women but have never been the focus of
clinical trials. Guidelines do not indicate the optimal dur-
ation of treatment because randomised controlled trials
have not been performed. As a consequence, there is large
practice variation on the subject. Whereas some clinicians
switch to ovulation induction with gonadotrophins with
or without IUI, others continue CC treatment with IUI in-
stead of intercourse.There are theoretically 4 treatment options that differ
in working mechanism, costs and treatment burden.
IUI is an alternative to intercourse, because it bypasses
the cervical barrier, optimises timing and shortens the
distance from spermatozoa to oocyt. However, IUI is
much more expensive than intercourse; because sperm
needs to be processed and extra hospital visits are
needed. Compared to ovulation induction with clomi-
phene citrate, gonadotrophins require frequent subcuta-
neous injections and frequent clinical visits due to
necessarity of close sonographic monitoring, and carry a
higher risk of multiple gestations. Ovulation induction
with CC will on average be about 750 euro less expen-
sive than ovulation induction with gonadotrophins.
Discontinuing CC and starting ovulation induction
with gonadotrophins and/or IUI should only be done if
the probability of conception is improved or the time to
conception reduced. There is a strong need for a large,
randomised study that compares costs and effects of CC
and gonadotrophins with or without IUI. The results of
the M-OVIN study will help to make evidence-based
guidelines for treatment in women with WHO type II
anovulation with CC-failure.
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